Enhanced solubility, oral bioavailability and anti-osteoporotic effects of raloxifene HCl in ovariectomized rats by Igepal CO-890 nanomicelles

References

• Apte S. 2010. Selecting surfactants for the maximum inhibition of the activity of the multidrug resistance efflux pump transporter, P-glycoprotein: conceptual development. J Excip Food Chem. 1:51–59.
   Google Scholar
• Bandela JJ, Anupama CH. 2009. Advanced pegylation for the development of raloxifene hydrochloride, BCS class II drug. J Young Pharmacists. 1:295–300.
   Google Scholar
• Bogman K, Peyer AK, Török M, Küsters E, Drewe J. 2001. HMG-CoA reductase inhibitors and P-glycoprotein modulation. Br J Pharmacol. 132:1183–1192.
   PubMed Web of Science ®Google Scholar
• Chang JH, Kochansky CJ, Shou M. 2006. The role of P-glycoprotein in the bioactivation of raloxifene. Drug Metab Dispos. 34:2073–2078.
   PubMed Web of Science ®Google Scholar
• Collnot EM, Baldes C, Wempe MF, Hyatt J, Navarro L, Edgar KJ, Schaefer UF, Lehr CM. 2006. Influence of vitamin E TPGS poly (ethylene glycol) chain length on apical efflux transporters in Caco-2 cell monolayers. J Control Rel. 111:35–40.
   PubMed Web of Science ®Google Scholar
• Collnot EM, Baldes C, Wempe MF, Kappl R, Hüttermann J, Hyatt JA, Edgar KJ, Schaefer UF, Lehr CM. 2007. Mechanism of inhibition of p-glycoprotein mediated efflux by vitamin E TPGS: influence on ATPase activity and membrane fluidity. Mol Pharmaceutics. 4:465–474.
   PubMed Web of Science ®Google Scholar
• Cornaire G, Woodley J, Hermann P, Cloarec A, Arellano C, Houin G. 2004. Impact of excipients on the absorption of P-glycoprotein substrates in vitro and in vivo. Int J Pharm. 278:119–131.
   PubMed Web of Science ®Google Scholar
• Delmas PD, Ensrud KE, Adachi JD, Harper KD, Sarkar S, Gennari C, Reginster JY, Pols HA, Recker RR, Harris ST, et al. 2002. Efficacy of raloxifene on vertebral fracture risk reduction in postmenopausal women with osteoporosis: four-year results from a randomized clinical trial. J Clin Endocrinol Metab. 87:3609–3617.
   PubMed Web of Science ®Google Scholar
• Epstein S. 2006. Update of current therapeutic options for the treatment of postmenopausal osteoporosis. Clin Ther. 28:151–173.
   PubMed Web of Science ®Google Scholar
• Fromm MF. 2004. Importance of P-glycoprotein at blood–tissue barriers. Trend Pharmacol Sci. 25:423–429.
   PubMed Web of Science ®Google Scholar
• Ghosh SK, Khatua PK, Bhattacharya SCh. 2004. Characterization of micelles of polyoxyethylene nonylphenol (Igepal) and its complexation with 3,7-diamino-2,8-dimethyl- 5-phenylphenazinium chloride. J Colloid Interface Sci. 275:623–631.
   PubMed Web of Science ®Google Scholar
• Hochner-Celnikier D. 1999. Pharmacokinetics of raloxifene and its clinical application. Eur J Obstet Gynecol Reprod Biol. 85:23–29.
   PubMed Web of Science ®Google Scholar
• Jeong EJ, Lin H, Hu M. 2004. Disposition mechanisms of raloxifene in the human intestinal Caco-2 model. J Pharmacol Exp Ther. 310:376–385.
   PubMed Web of Science ®Google Scholar
• Johnson BM, Charman WN, Porter CJ. 2002. An in vitro examination of the impact of polyethylene glycol 400, pluronic P85, and vitamin E da-tocopheryl polyethylene glycol 1000 succinate on P-glycoprotein efflux and enterocyte-based metabolism in excised rat intestine. Aaps J. 4:193–205.
   Google Scholar
• Kanis JA, Burlet N, Cooper C, Delmas PD, Reginster JY, Borgstrom F, Rizzoli R. 2008. European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int. 19:399–428.
   PubMed Web of Science ®Google Scholar
• Kipp JE. 2004. The role of solid nanoparticle technology in the parenteral delivery of poorly water-soluble drugs. Int J Pharm. 284:109–122.
   PubMed Web of Science ®Google Scholar
• Kocbek P, Baumgartner S, Kristl J. 2006. Preparation and evaluation of nanosuspensions for enhancing the dissolution of poorly soluble drugs. Int J Pharm. 312:179–186.
   PubMed Web of Science ®Google Scholar
• Kushwaha AK, Vuddanda PR, Karunanidhi P, Singh SK, Singh S. 2013. Development and evaluation of solid lipid nanoparticles of raloxifene hydrochloride for enhanced bioavailability. BioMed Res Int. 2013:584549.
   PubMed Web of Science ®Google Scholar
• Kushwaha AK, Vuddanda PR, Karunanidhi P, Singh SK, Singh S. 2013. Development and evaluation of solid lipid nanoparticles of raloxifene hydrochloride for enhanced bioavailability. BioMed Res Int. 2013:584549.
   PubMed Web of Science ®Google Scholar
• Kwon JT, Hwang SK, Jin H, Kim DS, Minai-Tehrani A, Yoon HJ, Choi M, Yoon TJ, Han DY, Kang YW, et al. 2008. Body distribution of inhaled fluorescent magnetic nanoparticles in the mice. J Occup Health. 50:1–6.
   PubMed Web of Science ®Google Scholar
• Lambert JK, Zaidi M, Mechanick JI. 2011. Male osteoporosis: epidemiology and the pathogenesis of aging bones. Curr Osteoporos Rep. 9:229–236.
   PubMedGoogle Scholar
• Lewis JS, Jordan VC. 2005. Selective estrogen receptor modulators (SERMs): mechanisms of anticarcinogenesis and drug resistance. Mutat Res. 591:247–263.
   PubMed Web of Science ®Google Scholar
• Mizuma T. 2009. Intestinal glucuronidation metabolism may have a greater impact on oral bioavailability than hepatic glucuronidation metabolism in humans: a study with raloxifene, substrate for UGT1A1, 1A8, 1A9, and 1A10. Int J Pharm. 378:140.
   PubMed Web of Science ®Google Scholar
• Riggs BL, Hartmann LC. 2003. Selective estrogen-receptor modulators – mechanisms of action and application to clinical practice. N Engl J Med. 348:618–629.
   PubMed Web of Science ®Google Scholar
• Riggs BL, Khosla S, Melton III LJ. 2002. Sex steroids and the construction and conservation of the adult skeleton. Endocr Rev. 23:279–302.
   PubMed Web of Science ®Google Scholar
• Riggs BL, Khosla S, Melton LJ. 1998. A unitary model for involutional osteoporosis: estrogen deficiency causes both type I and type II osteoporosis in postmenopausal women and contributes to bone loss in aging men. J Bone Miner Res. 13:763–773.
   PubMed Web of Science ®Google Scholar
• Sachs-Barrable K, Thamboo A, Lee SD, Wasan KM. 2007. Lipid excipients Peceol and Gelucire 44/14 decrease P-glycoprotein mediated efflux of rhodamine 123 partially due to modifying P-glycoprotein protein expression within Caco-2 cells. J Pharm Pharm Sci. 10:319–331.
   PubMed Web of Science ®Google Scholar
• Shah NV, Seth AK, Balaraman R, Aundhia CJ, Maheshwari RA, Parmar GR. 2016. Nanostructured lipid carriers for oral bioavailability enhancement of raloxifene. Design and in vivo study. J Adv Res. 7:423–434.
   PubMed Web of Science ®Google Scholar
• Shukla S, Abel B, Chufan EE, Ambudkar SV. 2017. Interactions effect of detergent micelle environment on P-glycoprotein (ABCB1)-ligand. J Biol Chem. 292:7066–7076.
   PubMed Web of Science ®Google Scholar
• Thakur PS, Singh N, Sangamwar AT, Bansal AK. 2017. Investigation of need of natural bioenhancer for a metabolism susceptible drug-raloxifene, in a designed self-emulsifying drug delivery system. AAPS PharmSciTech. 18:2529–2540.
   PubMed Web of Science ®Google Scholar
• Torchilin VP. 2007. Micellar nanocarriers: pharmaceutical perspectives. Pharm Res. 4:1–6.
   Google Scholar
• Tran TH, Poudel BK, Marasini N, Chi SC, Choi HG, Yong CS, Kim JO. 2013. Preparation and evaluation of raloxifene-loaded solid dispersion nanoparticle by spray-drying technique without an organic solvent. Int J Pharm. 443:50–57.
   PubMed Web of Science ®Google Scholar
• Tran TH, Poudel BK, Marasini N, Woo JS, Choi HG, Yong CS, Kim JO. 2013a. Development of raloxifene-solid dispersion with improved oral bioavailability via spray-drying technique. Arch Pharm Res. 36:86–93.
   PubMed Web of Science ®Google Scholar
• Tran TH, Ramasamy T, Cho HJ, Kim YI, Poudel BK, Choi HG, Yong CS, Kim JO. 2014. Formulation and optimization of raloxifene-loaded solid lipid nanoparticles to enhance oral bioavailability. J Nanosci Nanotech. 14:4820–4831.
   PubMed Web of Science ®Google Scholar
• Varshosaz J, Hassanzadeh F, Sadeghi-Aliabadi H, Firozian F. 2014. Uptake of etoposide in CT-26 cells of colorectal cancer using folate targeted dextran stearate polymeric micelles. BioMed Res Int. 2014:1–11.
   Web of Science ®Google Scholar
• Velpula A, Jukanti R, Janga KY, Sunkavalli S, Bandari S, Kandadi P, Veerareddy PR. 2013. Proliposome powders for enhanced intestinal absorption and bioavailability of raloxifene hydrochloride: effect of surface charge. Drug Dev Ind Pharm. 39:1895–1906.
   PubMed Web of Science ®Google Scholar
• Wempe MF, Wright C, Little JL, Lightner JW, Large SE, Caflisch GB, Buchanan CM, Rice PJ, Wacher VJ, Ruble KM, et al. 2009. Inhibiting efflux with novel non-ionic surfactants: Rational design based on vitamin E TPGS. Int J Pharm. 370:93–102.
   PubMed Web of Science ®Google Scholar